Cargando…

Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis?

Detalles Bibliográficos
Autor principal:	Jeon, Seong Ran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association for the Study of Intestinal Diseases 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934588/ https://www.ncbi.nlm.nih.gov/pubmed/29743828 http://dx.doi.org/10.5217/ir.2018.16.2.163

Ejemplares similares

Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study
por: Ogata, Haruhiko, et al.
Publicado: (2017)

Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
por: Ogata, Haruhiko, et al.
Publicado: (2017)

Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials
por: Zheng, Xin, et al.
Publicado: (2019)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis
por: Böhm, Stephan Karl, et al.
Publicado: (2014)

Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis
por: Kedia, Prashant, et al.
Publicado: (2007)

Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study
por: Ogata, Haruhiko, et al.
Publicado: (2018)

Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
por: Rubin, David T., et al.
Publicado: (2017)

Mesalazine granules promote disease clearance in patients with mild‐to‐moderate ulcerative colitis
por: Kruis, Wolfgang, et al.
Publicado: (2023)

The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine
por: Yarlas, Aaron, et al.
Publicado: (2021)

Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
por: Rubin, David T, et al.
Publicado: (2017)

Safety and efficacy of multimatrix mesalamine in paediatric patients with mild-to-moderate ulcerative colitis: a phase 3, randomised, double-blind study
por: Croft, Nicholas Michael, et al.
Publicado: (2023)

Combined Diosmectite and Mesalazine Treatment for Mild-to-Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Study
por: Jiang, Xue-Liang, et al.
Publicado: (2015)

Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis
por: Paridaens, Kristine, et al.
Publicado: (2023)

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial
por: Kruis, W, et al.
Publicado: (2009)

Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction
por: D’Haens, Geert, et al.
Publicado: (2023)

Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis
por: Cuffari, Carmen, et al.
Publicado: (2016)

A Case of Stevens–Johnson Syndrome Complicated with Multimatrix System Mesalamine in Ulcerative Colitis
por: Kanazawa, Mimari, et al.
Publicado: (2022)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014)

Is Long-Term Therapy With Thiopurines Effective for Maintaining Remission in Patients With Moderate-To-Severe Ulcerative Colitis?
por: Jeon, Seong Ran, et al.
Publicado: (2015)

Mesalazine-induced myopericarditis in a patient with ulcerative colitis
por: Asadi, Jalal, et al.
Publicado: (2017)

Recurrent Mesalazine-Induced Myopericarditis in a Patient with Ulcerative Colitis
por: Park, Eun Hye, et al.
Publicado: (2012)

Mesalazine-Induced Interstitial Nephritis in a Patient With Ulcerative Colitis
por: da Cunha Marques, José, et al.
Publicado: (2022)

Efficacy and safety of low-dose thalidomide combined with mesalazine in the treatment of refractory ulcerative colitis in adults
por: Chen, Jun-Rong, et al.
Publicado: (2022)

Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study
por: Willian, Mary Kaye, et al.
Publicado: (2018)

Crohn's Disease with Mesalazine Allergy that Was Difficult to Differentiate from Comorbid Ulcerative Colitis
por: Tsuboi, Rumiko, et al.
Publicado: (2018)

The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
por: Yuichiro, Ohtaki, et al.
Publicado: (2022)

Integrated Analysis Reveals the Targets and Mechanisms in Immunosuppressive Effect of Mesalazine on Ulcerative Colitis
por: Li, Rong, et al.
Publicado: (2022)

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
por: Oliveira, Lilliana, et al.
Publicado: (2011)

Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine
por: Zandman, Daniel B, et al.
Publicado: (2009)

Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study
por: Yarlas, Aaron, et al.
Publicado: (2018)

Efficacy of Combined Mesalazine Plus Corticosteroid Enemas for Diversion Colitis after Subtotal Colectomy for Ulcerative Colitis
por: Matsumoto, Satohiro, et al.
Publicado: (2016)

Is Adsorptive Granulocyte and Monocyte Apheresis Effective as an Alternative Treatment Option in Patients with Ulcerative Colitis?
por: Jeon, Seong Ran
Publicado: (2017)

Acute Pancreatitis due to pH-Dependent Mesalazine That Occurred in the Course of Ulcerative Colitis
por: Arai, Yoshinori, et al.
Publicado: (2011)

Mesalazine-related lung disease in a patient with ulcerative colitis: A case report
por: Huang, Po-Han, et al.
Publicado: (2018)

Systematic Evaluation of Randomized Clinical Trials of Huangqin Tang in Combination with Mesalazine for Ulcerative Colitis
por: Pan, Chengyu, et al.
Publicado: (2022)

Correction: The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
por: Ohtaki, Yuichiro, et al.
Publicado: (2023)

Efficacy of Long-Term 4.0 g/Day Mesalazine (Pentasa) for Maintenance Therapy in Ulcerative Colitis
por: Takeshima, Fuminao, et al.
Publicado: (2014)

Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine
por: Prenzler, Anne, et al.
Publicado: (2011)

Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report
por: Khanna, Raoul Kanav, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hsnmcio20j8gfetu4uv3pea299